Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV

Introduction People living with HIV (PLWH) are at a higher risk of severe disease with SARS-CoV-2 virus infection. COVID-19 vaccines are effective in most PLWH. However, suboptimal immune responses to the standard two-shot regimen are a concern, especially for those with moderate to severe immunodeficiency. An additional dose is recommended as part of the extended primary series in Taiwan. Herein, we study the efficacy of this additional shot in PLWH with mild immunodeficiency compared to that in healthy non-HIV people. Methods In total, 72 PLWH that were asymptomatic or with mild immunodeficiency (CD4 counts ≥200/mm3) and suppressed virology, and 362 healthcare workers of our hospital were enrolled. None of the participants had a history of SARS-CoV-2 infection. They received mRNA-1273 and ChAdOx1 vaccines. Anti-SARS-CoV-2 neutralizing and anti-Spike IgG antibodies, and SARS-CoV-2-specific T cell responses were evaluated. Results The standard two-shot regimen elicited lower responses in PLWH than the healthcare workers without HIV infection, although the difference was statistically insignificant. They had comparable levels of neutralizing and anti-Spike antibodies and comparable effector CD4+ and CD8+ T cell responses. The third shot boosted the SARS-CoV-2 immunity significantly more with better antibody responses and higher IFN-γ and IL-2 responses of the CD4+ and CD8+ T cells in PLWH compared to those without HIV. Upon in vitro stimulation with extracted Wuhan strain SARS-CoV-2 proteins, CD8+ T cells from PLWH after 3 shots had more durable effector responses than the non-HIV controls with extended time of stimulation. Conclusion This subtle difference between PLWH and non-HIV people implied immune exhaustion with two shots in non-HIV people. Slightly compromised immunity in PLWH indeed preserved the functional capacity for further response to the third shot or natural infection.

[1]  A. Naing,et al.  Interleukin-10 in cancer immunotherapy: from bench to bedside. , 2023, Trends in cancer.

[2]  M. Lown,et al.  Non-pharmaceutical interventions and risk of COVID-19 infection: survey of U.K. public from November 2020 – May 2021 , 2023, BMC Public Health.

[3]  E. Ang,et al.  Heterogenous antibody and T‐cell responses to SARS‐CoV‐2 mRNA vaccines among immunocompromised young people , 2023, Clinical and translational medicine.

[4]  Tse-Ching Chen,et al.  The origin of regulatory from the effector cells in LAG‐3‐marked Th1 immunity against severe influenza virus infection , 2022, Immunology.

[5]  T. Wu,et al.  COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection , 2022, Journal of Biomedical Science.

[6]  E. Abboud,et al.  Practice of non-pharmaceutical interventions against COVID-19 and reduction of the risk of influenza-like illness: a cross-sectional population-based study , 2022, Journal of pharmaceutical policy and practice.

[7]  H. Blanché,et al.  Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population , 2022, Scientific reports.

[8]  D. Cuadros,et al.  Risk of mortality in HIV-infected COVID-19 patients: A systematic review and meta-analysis , 2022, Journal of Infection and Public Health.

[9]  Han-i Wang,et al.  The COVID-19 Vaccination and Vaccine Inequity Worldwide: An Empirical Study Based on Global Data , 2022, International journal of environmental research and public health.

[10]  C. Agrati,et al.  Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Kochhar,et al.  Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review , 2022, The Lancet Global Health.

[12]  V. Tergaonkar,et al.  Unraveling B cell trajectories at single cell resolution. , 2022, Trends in immunology.

[13]  Jennifer Abbasí The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity. , 2021, JAMA.

[14]  Michael J. Ryan,et al.  Considerations in boosting COVID-19 vaccine immune responses , 2021, The Lancet.

[15]  Yonghai Dong,et al.  HIV infection and risk of COVID-19 mortality , 2021, Medicine.

[16]  A. Gawande,et al.  Mass-Vaccination Sites - An Essential Innovation to Curb the Covid-19 Pandemic. , 2021, The New England journal of medicine.

[17]  Efstathios D. Gennatas,et al.  Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity , 2021, The Lancet Infectious Diseases.

[18]  C. Mangurian,et al.  Caring for the Caregivers - Covid-19 Vaccination for Essential Members of the Health Care Team. , 2021, The New England journal of medicine.

[19]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[20]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[21]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[22]  A. H. Mohammed,et al.  The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients. , 2020, AIDS reviews.

[23]  S. Halstead,et al.  COVID 19 Vaccines: Should we fear ADE? , 2020, The Journal of infectious diseases.

[24]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[25]  Shu-Min Lin,et al.  Relative COVID-19 Viral Persistence and Antibody Kinetics , 2020, medRxiv.

[26]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[27]  T. Colbourn,et al.  Three lessons for the COVID-19 response from pandemic HIV , 2020, The Lancet HIV.

[28]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[29]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[30]  C. Chiu,et al.  IL-10 inhibits neuraminidase-activated TGF-β and facilitates Th1 phenotype during early phase of infection , 2015, Nature Communications.

[31]  P. Böelle,et al.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Taljaard,et al.  A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario , 2014, BMC Public Health.

[33]  V. Triant Cardiovascular Disease and HIV Infection , 2013, Current HIV/AIDS Reports.

[34]  J. Brooks,et al.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  L. Iacoviello,et al.  HIV Infection, Antiretroviral Therapy and Cardiovascular Risk , 2010, Mediterranean journal of hematology and infectious diseases.

[36]  F. Schmidt Meta-Analysis , 2008 .

[37]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[38]  J. Bach Non‐Th2 Regulatory T‐Cell Control of Th1 Autoimmunity , 2001, Scandinavian journal of immunology.

[39]  C. Faraker Rapid review , 1998, Cytopathology : official journal of the British Society for Clinical Cytology.

[40]  C. Agrati,et al.  Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count , 2021, SSRN Electronic Journal.

[41]  Rashedul Hasan,et al.  Corporate Governance Dynamics and Quality of Bank and Insurance Boards An empirical study based on global data , 2019 .

[42]  L. Trümper From bench to bedside , 2005, Medizinische Klinik.

[43]  A. R.,et al.  Review of literature , 1951, American Potato Journal.